e-learning
resources
Copenhagen 2005
Sunday 18.09.2005
Progresses in lung fibrosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Proteomic analysis of BALf in systemic sclerosis patients (SSp) with or without pulmonary fibrosis (ILD)
A. M. Bardoni, R. Salvini, I. Passadore, C. Di Poto, C. Montecucco, E. Pozzi, F. Meloni, A. M. Fietta (Pavia, Italy)
Source:
Annual Congress 2005 - Progresses in lung fibrosis
Session:
Progresses in lung fibrosis
Session type:
Oral Presentation
Number:
1320
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. M. Bardoni, R. Salvini, I. Passadore, C. Di Poto, C. Montecucco, E. Pozzi, F. Meloni, A. M. Fietta (Pavia, Italy). Proteomic analysis of BALf in systemic sclerosis patients (SSp) with or without pulmonary fibrosis (ILD). Eur Respir J 2005; 26: Suppl. 49, 1320
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
The new challenge of CTD-ILD: from basic science to clinical setting
Related content which might interest you:
Contribute of BAL proteomic analysis in sarcoidosis (S) and in idiopathic pulmonary fibrosis (IPF/UIP)
Source: Eur Respir J 2006; 28: Suppl. 50, 564s
Year: 2006
Auto-antibody subsets and extent of pulmonary fibrosis in systemic sclerosis (SSc)
Source: Eur Respir J 2005; 26: Suppl. 49, 202s
Year: 2005
Relationship between MIF and cellular pattern in BAL of patients with sarcoidosis, systemic sclerosis, idiopathic pulmonary fibrosis
Source: Eur Respir J 2003; 22: Suppl. 45, 377s
Year: 2003
Comparative proteome analysis of lung tissue from patients with idiopathic pulmonary fibrosis (IPF) and non-specific interstitial pneumonia (NSIP)
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013
Autoimmunity profile in patients with combined pulmonary fibrosis and emphysema (CPFE)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
Clinico-laboratory characteristics of patients with interstitial lung disease (ILD) in polymyositis-dermatomyositis (PM/DM)
Source: Eur Respir J 2003; 22: Suppl. 45, 46s
Year: 2003
Expression of mRNA of selected inflammatory markers in BALf cells from patients with sarcoidosis and idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – IPF: from the bench to the bedside
Year: 2017
Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing extents of lung fibrosis: the SENSCIS trial
Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new?
Year: 2019
BALF proteomic analysis in polymyositis/dermatomyositis patients with interstitial lung disease
Source: Annual Congress 2009 - Bronchoalveolar lavage and phenotyping in diffuse parenchymal lung disease
Year: 2009
The circulating metabolome in idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia
Year: 2019
BAL features in patients with systemic scleroris (SSc)
Source: Eur Respir J 2001; 18: Suppl. 33, 410s
Year: 2001
Outcome differences between idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILD) - data from the EXCITING registry
Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries
Year: 2018
Interstitial lung disease (ILD) in association with polymyositis-dermatomyositis (PM/DM) with predominant lymphocytic alveolitis and anti-Jo-1-antibodies
Source: Eur Respir J 2002; 20: Suppl. 38, 586s
Year: 2002
Genomic comparison of fibrotic rheumatoid arthritis-associated ILD and idiopathic pulmonary fibrosis
Source: International Congress 2015 – Connective tissue disorders
Year: 2015
Interstitial lung disease with ANCA-associated vasculitis (AAV-ILD): Clinical features and survival compared to patients with ILD associated with systemic sclerosis and IPF
Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key
Year: 2020
Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases
Year: 2013
Features and functional deterioration in interstitial lung disease (ILD) asociated to rheumatoid arthritis (RA)
Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases
Year: 2019
Etablishing rhesus model of pulmonary fibrosis (PF) for the new drug evaluation
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Analysis of baseline characteristics by emphysema extent in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – ILDs: clinical aspects
Year: 2017
Interstitial lung disease (ILD) in patients with polymyositis/dermatomyositis (PM/DM): clinical features and response to treatment in 6 cases
Source: Eur Respir J 2001; 18: Suppl. 33, 528s
Year: 2001
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept